| Symbol
| GAS6
| contributors: mct/npt - updated : 25-01-2016
|
| HGNC name
| growth arrest-specific 6
|
| HGNC id
| 4168
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in both glioma and vascular cells and predict poor prognosis in glioblastoma multiformis patients (Hutterer 2008) | | constitutional
|
|
| --over
|
|
in patients with RPL (recurrent pregnancy loss)  | | constitutional
|
|
| --over
|
| |
in systemic lupus erythematosus, with lupus nephritis or cutaneous vasculitis | | constitutional
|
|
| --over
|
| |
GAS6 serum concentrations are significantly increased in Preeclampsia (PE) during pregnancy | | constitutional
|
|
| --over
|
| |
associated with venous thromboembolic disease | |
| Susceptibility
|
to atherothrombotic disease |
| Variant & Polymorphism
SNP
| SNP c834+7G>A in intron 8 increasing the risk of atherothrombotic disease |
| 
|
Candidate gene
| Marker
| potential to serve as a SLE disease activity marker | Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | endocrine | thyroid | |
| TYRO3/AXL-GAS6 autocrine circuit sustains the malignant features of thyroid cancer cells and targeting the circuit could offer a novel therapeutic approach in this cancer | | cancer | brain | glioma/neuroblstoma | |
| specific targeting of the Axl/Gas6 signaling pathway may represent a potential new approach for glioma treatment | | cancer | digestive | colon | |
| unique inhibitory role during the progression of intestinal tumors associated with suppression of stromal immune reactions, suggesting a novel therapeutic approach for colorectal cancer patients | | cancer | endocrine | pancreas | |
| GAS6 inhibition with low-dose warfarin or other AXL-targeting agents may improve outcome in patients with AXL-expressing tumors |
| | |